Tag Archives: Jim Greenwood

A Closer Look at AHIP’s Claims

new-bio-logo

This morning, in a letter to the editor of the New York Times, Marilyn Tavenner, President and CEO of America’s Health Insurance Plans (AHIP), attempted to lay the blame for higher healthcare costs and insurance premiums at the feet of America’s cutting-edge biopharma companies. AHIP has been peddling these falsehoods and misinformation for years.  Tavenner’s (and her organization’s) claims are—at best—uninformed. At worst, they are outright distortions deployed to hide the facts from patients who Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Jim Greenwood on “Time is Precious”

TimeIsPrecious_ScreenCap

Jim Greenwood, President & CEO, Biotechnology Innovation Organization discusses the organizations new campaign, Time is Precious. Greenwood says, “… if we are going to continue to create new treatments and cures we are going to have to continue to invest and attract investment capital.”  Watch the full interview below.

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Jim Greenwood

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. Greenwood’s letter discusses the problems that expanded use of specialty tier cost-sharing by the insurance industry are posing for patients, limiting their access to lifesaving therapies and cures. Breakthrough treatments cost billions of dollars, and investors will only take on such risks if they can expect a reasonable return on their investment. The full text of the letter is below: To Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Jim Greenwood on the Road: Opening Bell at NASDAQ

Jim Ringing Nasdaq Bell

Jim Greenwood, BIO’s President and CEO, rang the opening bell this morning at the NASDAQ MarketSite in New York. Joining him on the stage were a number of BIO members and affiliates, including NewYorkBIO Executive Director Nathan Tinker, Pennsylvania Bio President Christopher Molineaux, DelawareBio Chairman Christopher Yochim, and BioNJ President Debbie Hart. Several BIO member companies were also represented, including Acorda Therapeutics President and CEO Ron Cohen, who also serves as Vice Chair of BIO’s Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Wall Street Journal Highlights Promising Gene Therapy Advances

Jim Greenwood

Yesterday, bluebird bio reported some very uplifting news at the annual meeting of the American Society of Hematology. Two patients with beta-thalassemia, a genetic disorder which normally requires regular blood transfusions, have been able to forgo transfusions for at least five months following a gene therapy treatment from bluebird. The Wall Street Journal’s Ron Winslow reports: Bluebird bio’s treatment involves extracting blood stem cells from a patient, treating them with a functioning version of the defective Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,